Sector News

Valeant heeds calls for new CEO

March 21, 2016
Life sciences

Valeant CEO J. Michael Pearson is on his way out–and this time, it’s for good.

The Canadian drugmaker has started searching for a new skipper to replace Pearson as it struggles under the threat of debt default, a still-brewing scandal and governmental scrutiny. Pearson will remain at the helm until the company names his successor, Valeant said in a Monday statement.

The change is no surprise, considering the disastrous few weeks since Pearson returned from a medical leave of absence. Last week, he acknowledged that, a) a delay on the company’s’ regulatory filings–thanks to accounting missteps related to Philidor, the subject of last fall’s channel-stuffing allegations–put Valeant at risk of defaulting on its debt, and b) several of the company’s businesses were seriously underperforming. Investors didn’t much like the news, sending shares crashing down by more than 50%.

And Pearson was already on a short leash: The company reportedly compiled a short list of replacements, including former Sanofi CEO Chris Viehbacher and former Schering-Plough chief Fred Hassan while he was out with pneumonia, and the board almost didn’t let him retake his old post.

The CEO search wasn’t the only bomb Valeant dropped Monday, though. In the same statement, it attributed those Philidor-related accounting blunders to “improper conduct” from former CFO Howard Schiller and the company’s corporate comptroller, which “resulted in the provision of incorrect information.” The company has asked Schiller, still a Valeant director, to resign, but so far he hasn’t.

And according to the ad hoc committee assembled to investigate the channel-stuffing claims, the “tone at the top of the organization and the performance-based environment”–which valued achieving challenging targets as a key performance metric–“may have been contributing factors resulting in the company’s improper revenue recognition.”

All that fog surrounding Valeant’s accounting procedures could make the CEO job a tough sell. And if that wasn’t enough to scare off potential candidates, the company is still dealing with a plethora of other problems. It’s currently under multiple investigations–including ones from the Securities and Exchange Commission and Congress. Payers have frozen out some of its key products. Debtors are reportedly preparing to wrangle tougher new agreements now that the company has its back against the wall–and the list goes on.

But one thing about the search for a successor is clear: Bill Ackman, head of No. 2 Valeant shareholder Pershing Square Capital Management and onetime Pearson enthusiast, will be on hand to help spearhead it. After vowing action amid the share-price freefall last week, Ackman Monday took a seat alongside Pershing Square’s vice chairman Steve Fraidin at Valeant’s boardroom table, with director Katharine Stevenson voluntarily stepping down to make space for him.

“I am looking forward to working with the board to identify new leadership for Valeant,” Ackman said in a statement. “The company’s large scale and dominant franchises in eye care, dermatology, GI and other therapeutic areas, coupled with its extraordinarily low valuation, present a spectacular opportunity for a world-class healthcare executive.”

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”